We use cookies on our website. Carry on browsing if you’re happy with this or find out more



Two senior appointments strengthen team

Kymab makes senior appointments at Chief Scientific Officer and Vice President and Head of Business Development.

Kymab announced the senior appointments of Dr Steve Arkinstall as Chief Scientific Officer and Dr Nigel Clarke as Vice President and Head of Business Development.

"Following the successful US$40 million fundraising in May, we are delighted to announce the appointments of Steve and Nigel to Kymab's senior management team," said Christian Groendahl, CEO of Kymab. "Steve's scientific know-how and expertise in developing high quality drugs at Merck Serono will enable us to further advance our proprietary pipeline of first-in-class therapeutic human monoclonal antibodies in areas of significant unmet medical need and will strengthen Kymab’s expertise in human genetics."

Steve Arkinstall brings overs 25 years' experience across biopharmaceutical research and development, having worked across several disease areas and specialising in drug target validation, R&D strategic design, antibody discovery and protein engineering. He joins Kymab from Merck Serono, where over his 16-year career he has held a number of senior management roles including leadership of the Serono Research Institute in Boston as well as head of Global Technologies and External Innovation.

Prior to joining Serono, Steve was in research at GlaxoWellcome. He is a respected leader in drug discovery and a global expert across a range of therapeutic, scientific and technical areas supporting drug discovery and development.

"Nigel's strong track record in deal making will be invaluable in maximising the potential of the KymouseTM platform," continued Dr Groendahl.

Nigel Clark has 20 years’ experience in the biopharmaceutical industry at both public and private companies. He is a recognised deal maker and has completed over 20 major transactions. He was previously Chief Business Officer at Syntaxin and negotiated the sale of the company to Ipsen Pharma for €158 million. Prior to Syntaxin, Nigel was Head of Business Development at Vernalis, where he was responsible for commercial operations, a role he held for seven years.

"We look forward to benefiting from both Steve and Nigel’s experience as we and build Kymab into a global biotechnology company," concluded Dr Groendahl.

Allan Bradley, Founder and previously Chief Scientific Officer will continue as an essential member on the Executive Leadership team. He will serve as Chief Technology Officer driving further advances in Kymab’s proprietary technology platforms, strategic thinking in human population genetics and establishing a vaccine discovery capability. In addition, Allan will continue to serve as a member of the Board of Directors for Kymab.

Find out which events we'll be attending this year

View events